241 related articles for article (PubMed ID: 30496374)
21. The importance of sodium/iodide symporter (NIS) for thyroid cancer management.
Carvalho DP; Ferreira AC
Arq Bras Endocrinol Metabol; 2007 Jul; 51(5):672-82. PubMed ID: 17891230
[TBL] [Abstract][Full Text] [Related]
22. Advances in Na(+)/I(-) symporter (NIS) research in the thyroid and beyond.
Dohán O; Carrasco N
Mol Cell Endocrinol; 2003 Dec; 213(1):59-70. PubMed ID: 15062574
[TBL] [Abstract][Full Text] [Related]
23. [The practical relevance of the sodium iodide symporter].
Spitzweg C
Z Arztl Fortbild Qualitatssich; 2004 May; 98 Suppl 5():25-32. PubMed ID: 15255310
[TBL] [Abstract][Full Text] [Related]
24. Phosphoinositide-3-kinase inhibition induces sodium/iodide symporter expression in rat thyroid cells and human papillary thyroid cancer cells.
Kogai T; Sajid-Crockett S; Newmarch LS; Liu YY; Brent GA
J Endocrinol; 2008 Nov; 199(2):243-52. PubMed ID: 18762555
[TBL] [Abstract][Full Text] [Related]
25. Molecular characterization of V59E NIS, a Na+/I- symporter mutant that causes congenital I- transport defect.
Reed-Tsur MD; De la Vieja A; Ginter CS; Carrasco N
Endocrinology; 2008 Jun; 149(6):3077-84. PubMed ID: 18339708
[TBL] [Abstract][Full Text] [Related]
26. Alpha-lipoic acid induces sodium iodide symporter expression in TPC-1 thyroid cancer cell line.
Choi HJ; Kim TY; Ruiz-Llorente S; Jeon MJ; Han JM; Kim WG; Shong YK; Kim WB
Nucl Med Biol; 2012 Nov; 39(8):1275-80. PubMed ID: 22995901
[TBL] [Abstract][Full Text] [Related]
27. Implications of the molecular characterization of the sodium-iodide symporter (NIS).
Schmutzler C; Köhrle J
Exp Clin Endocrinol Diabetes; 1998; 106 Suppl 3():S1-10. PubMed ID: 9865544
[TBL] [Abstract][Full Text] [Related]
28. Biology and clinical application of the NIS gene.
Elisei R; Vivaldi A; Pacini F
Tumori; 2003; 89(5):523-8. PubMed ID: 14870777
[TBL] [Abstract][Full Text] [Related]
29. A Nonpump Function of Sodium Iodide Symporter in Thyroid Cancer via Cross-talk with PTEN Signaling.
Feng F; Yehia L; Ni Y; Chang YS; Jhiang SM; Eng C
Cancer Res; 2018 Nov; 78(21):6121-6133. PubMed ID: 30217930
[TBL] [Abstract][Full Text] [Related]
30. A perspective view of sodium iodide symporter research and its clinical implications.
Riesco-Eizaguirre G; Santisteban P
Eur J Endocrinol; 2006 Oct; 155(4):495-512. PubMed ID: 16990649
[TBL] [Abstract][Full Text] [Related]
31. Identification of in vivo phosphorylation sites and their functional significance in the sodium iodide symporter.
Vadysirisack DD; Chen ES; Zhang Z; Tsai MD; Chang GD; Jhiang SM
J Biol Chem; 2007 Dec; 282(51):36820-8. PubMed ID: 17913707
[TBL] [Abstract][Full Text] [Related]
32. An Intramolecular Ionic Interaction Linking Defective Sodium/Iodide Symporter Transport to the Plasma Membrane and Dyshormonogenic Congenital Hypothyroidism.
Bernal Barquero CE; Martín M; Geysels RC; Peyret V; Papendieck P; Masini-Repiso AM; Chiesa AE; Nicola JP
Thyroid; 2022 Jan; 32(1):19-27. PubMed ID: 34726525
[No Abstract] [Full Text] [Related]
33. A Novel SLC5A5 Variant Reveals the Crucial Role of Kinesin Light Chain 2 in Thyroid Hormonogenesis.
Martín M; Modenutti CP; Gil Rosas ML; Peyret V; Geysels RC; Bernal Barquero CE; Sobrero G; Muñoz L; Signorino M; Testa G; Miras MB; Masini-Repiso AM; Calcaterra NB; Coux G; Carrasco N; Martí MA; Nicola JP
J Clin Endocrinol Metab; 2021 Jun; 106(7):1867-1881. PubMed ID: 33912899
[TBL] [Abstract][Full Text] [Related]
34. A novel mechanism of sodium iodide symporter repression in differentiated thyroid cancer.
Smith VE; Read ML; Turnell AS; Watkins RJ; Watkinson JC; Lewy GD; Fong JC; James SR; Eggo MC; Boelaert K; Franklyn JA; McCabe CJ
J Cell Sci; 2009 Sep; 122(Pt 18):3393-402. PubMed ID: 19706688
[TBL] [Abstract][Full Text] [Related]
35. The complex regulation of NIS expression and activity in thyroid and extrathyroidal tissues.
Riesco-Eizaguirre G; Santisteban P; De la Vieja A
Endocr Relat Cancer; 2021 Sep; 28(10):T141-T165. PubMed ID: 34387194
[TBL] [Abstract][Full Text] [Related]
36. The sodium/iodide symporter: state of the art of its molecular characterization.
Darrouzet E; Lindenthal S; Marcellin D; Pellequer JL; Pourcher T
Biochim Biophys Acta; 2014 Jan; 1838(1 Pt B):244-53. PubMed ID: 23988430
[TBL] [Abstract][Full Text] [Related]
37. microRNA-339-5p modulates Na+/I- symporter-mediated radioiodide uptake.
Lakshmanan A; Wojcicka A; Kotlarek M; Zhang X; Jazdzewski K; Jhiang SM
Endocr Relat Cancer; 2015 Feb; 22(1):11-21. PubMed ID: 25404690
[TBL] [Abstract][Full Text] [Related]
38. Dimerization of the Sodium/Iodide Symporter.
Thompson RJ; Fletcher A; Brookes K; Nieto H; Alshahrani MM; Mueller JW; Fine NHF; Hodson DJ; Boelaert K; Read ML; Smith VE; McCabe CJ
Thyroid; 2019 Oct; 29(10):1485-1498. PubMed ID: 31310151
[No Abstract] [Full Text] [Related]
39. Benign nonfunctioning thyroid adenomas are characterized by a defective targeting to cell membrane or a reduced expression of the sodium iodide symporter protein.
Tonacchera M; Viacava P; Agretti P; de Marco G; Perri A; di Cosmo C; de Servi M; Miccoli P; Lippi F; Naccarato AG; Pinchera A; Chiovato L; Vitti P
J Clin Endocrinol Metab; 2002 Jan; 87(1):352-7. PubMed ID: 11788674
[TBL] [Abstract][Full Text] [Related]
40. [Estimation of sodium/iodide symporter gene expression (NIS) in thyroid cancer by RT-PCR technique (preliminary study)].
Tosiek M; Pomorski L; Balcerczak E; Mirowski M; Czyz W
Endokrynol Pol; 2005; 56(1):25-9. PubMed ID: 16335670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
